[
    [
        {
            "time": "",
            "original_text": "【国盛证券张金洋团队】凯莱英中报点评：收入端略超预期，临床阶段项目迅猛增长为后续提供成长动力",
            "features": {
                "keywords": [
                    "凯莱英",
                    "中报点评",
                    "收入端",
                    "超预期",
                    "临床阶段项目",
                    "成长动力"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【国盛证券张金洋团队】凯莱英中报点评：收入端略超预期，临床阶段项目迅猛增长为后续提供成长动力",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]